Lexeo Therapeutics Inc LXEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LXEO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $12.16
- Day Range
- $11.99–12.86
- 52-Week Range
- $9.00–22.33
- Bid/Ask
- $4.85 / $12.54
- Market Cap
- $411.84 Mil
- Volume/Avg
- 377,218 / 111,354
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 58
- Website
- https://www.lexeotx.com
Valuation
|
Metric
|
LXEO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.93 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LXEO
|
|---|---|
Quick Ratio | 7.05 |
Current Ratio | 7.21 |
Interest Coverage | −336.86 |
Quick Ratio
LXEO
Profitability
|
Metric
|
LXEO
|
|---|---|
Return on Assets (Normalized) | −70.48% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
LXEO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xlyhzmzw | Gkl | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jsbrnhgv | Sybcm | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dmdqjhnv | Fhrgv | $97.8 Bil | |
MRNA
| Moderna Inc | Qzhjbmzwq | Zpfw | $41.3 Bil | |
ARGX
| argenx SE ADR | Lrpznskqc | Mpmjp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gxrhngpjh | Ykkcf | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xcbykvrk | Flywmll | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zwhkmfb | Xmmfxh | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Whchdmhz | Rzbdqh | $12.5 Bil | |
INCY
| Incyte Corp | Tzdfdrlq | Zqqpzbb | $11.6 Bil |